infliximab induces increase in triglyceride levels in psoriatic arthritis patients
Clicks: 246
ID: 181982
2011
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
246 views
52 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #44 of 171 articles by views in Applied Surface Science
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 171 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC) and its fractions, inflammatory markers, and prednisone use were evaluated. Results. The comparisons of lipid levels between baseline and after three months (3M) of anti-TNF therapy showed that there was a significant increase in mean triglycerides (117.8±49.7 versus 140.1±64.1 mg/dL, P=0.028) and VLDL-c (23.6±10.5 versus 28.4±13.7 mg/dL, P=0.019) levels. In contrast, there were no differences in the mean TC (P=0.28), LDL-c (P=0.42), and HDL-c (P=0.26) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P>0.05). Positive correlations were found between VLDL-c and CRP (r=0.647, P=0.009) and between triglycerides and CRP (r=0.604, P=0.017) levels at 3M. ESR reduction was observed after 3M (P=0.04). Mean prednisone dose remained stable at beginning and at 3M (P=0.37). Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months.
| Reference Key |
castro2011clinicalinfliximab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Karla R. Castro;Nádia E. Aikawa;Carla Gonçalves Saad;Júlio C. B. Moraes;Ana C. Medeiros;Licia Maria H. Mota;Clovis A. A. Silva;Eloísa Bonfá;Jozélio F. Carvalho |
| Journal | Applied Surface Science |
| Year | 2011 |
| DOI |
10.1155/2011/352686
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.